How do you sequence treatment for patients with HER2-mutant metastatic NSCLC?

It is a challenge that we should face with great excitement, as HER2 in lung cancer, up until recently, was EGFR’s poor sibling, as so astutely highlighted by Dr. Carbone in his recent NEJM editorial. Indeed, while we have seen dramatic changes with generations of EGFR TKIs and now combinations, such as FLAURA2/MARIPOSA transforming the care of EGFR-mutated advanced and more recently also early stage NSCLC (ADAURA/LAURA), for 20 years HER2 mutations have remained the ugly duckling in the lung ca...